EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Barriers to T Cell Functionality in the Glioblastoma Microenvironment

Noor E Nader iD, Stephen C Frederico iD, Tracy Miller, Sakibul Huq, Xiaoran Zhang, Gary Kohanbash iD, Constantinos G Hadjipanayis

Cancers · 26.09.2024 · 16 (19) · 3273

DOI: 10.3390/cancers16193273 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.09.2024. Verfasst von Noor E Nader und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is an aggressive primary brain tumor depicted by a cold tumor microenvironment, low immunogenicity, and limited effective therapeutic interventions. Its location in the brain, a highly immune-selective organ, acts as a barrier, limiting immune access and promoting GBM dissemination, despite therapeutic interventions. Currently, chemotherapy and radiation combined with surgical resection are the standard of care for GBM treatment. Although immune checkpoint blockade has revolutionized the treatment of solid tumors, its observed success in extracranial tumors has not translated into a significant survival benefit for GBM patients. To develop effective immunotherapies for GBM, it is vital to tailor treatments to overcome the numerous immunosuppressive barriers that inhibit T cell responses to these tumors. In this review, we address the unique physical and immunological barriers that make GBM challenging to treat. Additionally, we explore potential therapeutic mechanisms, studied in central nervous system (CNS) and non-CNS cancers, that may overcome these barriers. Furthermore, we examine current and promising immunotherapy clinical trials and immunotherapeutic interventions for GBM. By highlighting the array of challenges T cell-based therapies face in GBM, we hope this review can guide investigators as they develop future immunotherapies for this highly aggressive malignancy.

Schlagwörter

Stichwörter der Autor:innen

CNSGBMT cellbrainglioblastoma

Autor:innen und Institutionen

  • School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Harvard Medical School, Boston, MA 02115, USA.
  • Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Sloan Kettering Memorial Cancer Center, New York, NY 10065, USA.

ORCID-Profile: Noor E Nader, Stephen C Frederico, Gary Kohanbash

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Nader, N. E., Frederico, S. C., Miller, T., Huq, S., Zhang, X., Kohanbash, G., & Hadjipanayis, C. G. (2024). Barriers to T Cell Functionality in the Glioblastoma Microenvironment. Cancers, 16(19), 3273. https://doi.org/10.3390/cancers16193273

Vancouver

Nader NE, Frederico SC, Miller T, Huq S, Zhang X, Kohanbash G, et al. Barriers to T Cell Functionality in the Glioblastoma Microenvironment. Cancers. 2024;16(19):3273. doi:10.3390/cancers16193273

BibTeX
@article{Nader2024,
  author = {Nader, Noor E and Frederico, Stephen C and Miller, Tracy and Huq, Sakibul and Zhang, Xiaoran and Kohanbash, Gary and Hadjipanayis, Constantinos G},
  title = {Barriers to T Cell Functionality in the Glioblastoma Microenvironment},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {19},
  pages = {3273},
  doi = {10.3390/cancers16193273}
}
Kostenlos starten →